In Re: Purdue Pharma L.P.

CourtDistrict Court, S.D. New York
DecidedOctober 13, 2021
Docket7:21-cv-07966
StatusUnknown

This text of In Re: Purdue Pharma L.P. (In Re: Purdue Pharma L.P.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re: Purdue Pharma L.P., (S.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ge

In te: PURDUE PHARMA LP., et al, nn Uh ENT . {| DOC #: ED This Filing Relates to LDATE FLED, 10/2 Toowil x Mn oe a fo □ if WILLIAM K. HARRINGTON, UNITED STATES TRUSTEE, Appellant, 21 cv 7969 (CM) Vv. 21 cv 7966 (CM} PURDUE PHARMA LP., et al., Appellees. □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ MEMORANDUM AND ORDER DENYING WITHOUT PREJUDICE THE UNITED STATES TRUSTEE’S EMERGENCY MOTION FOR A STAY PENDING APPEAL McMahon, J.: Before the Court is the motion by the United States Trustee, William K. Harrington, (the “US. Trustee” or “Movant”) for an emergency stay pending his appeals from two orders of the United States Bankruptcy Court for the Southern District of New York (Drain, B.J.) — which will be referred to as the Confirmation Order and the Advance Order. The Peter Ballantyne Cree Nation, Certain Canadian Municipality Creditors including the City of Grand Prairie; the City of Brantford; the City of Grande Prairie; the City of Lethbridge; and the City of Wetaskiwin have formally joined in the U.S. Trustee’s motion. (See Dkts. 35, 36 and Dkts. 36, 37 in Case Nos. 21-cv-7969 and 21-cv-7966 respectively). At oral argument, counsel for the State of Maryland clarified that several of the states, including Maryland, while not formally joined in this motion, have their own stay motions before the Bankruptcy Court and agree that a stay is necessary.

The stay is sought in the U.S. Trustee’s two above-captioned pending appeals, which are in the process of being consolidated with all pending appeals before me for all purposes before this court.! Movants assert that a stay is needed in order to preclude any possible finding of equitable mootness — a doctrine alive and well in the Second Circuit — which could result in appellants and those aligned with their position losing their right to have their appeal heard, The court entered a temporary restraining order (“TRO”) halting all activity authorized by the Confirmation Order and the Advance Order on Sunday, October 10, and heard oral argument on the motions at a hearing on October 12. For the reasons outlined below, the U.S. Trustee’s motion is DENIED WITHOUT PREJUDICE on conditions specified at the conclusion of this opinion. The temporary restraining order will expire when the stipulation discussed at the conclusion of this opinion is docketed. BACKGROUND In order to get this decision out promptly, I have liberally used background information from the memorandum of law filed by the United States Trustee in support of his motion. A. The Underlying Bankruptcy The above-captioned appeals arise from a complex bankruptcy litigation in the United States Bankruptey Court for the Southern District of New York, which involves hundreds of thousands of claims against the debtors’* (“Debtors” or “Purdue”) for their alleged role in opioid

| At the present time there are thirteen such appeals docketed and assigned to me. I was advised at yesterday’s hearing that at least one more such appeal — by the State of Vermont — has not yet been docketed. A consolidation order ts being entered simultaneously with the release of this opinion. 2 The Debtors in these cases are as follows: Purdue Pharma L.P., Purdue Pharma Inc., Purdue Transdermal Technologies L.P., Purdue Pharma Manufacturing L.P., Purdue Pharmaceuticals L.P., Imbrium Therapeutics L.P., Adion Therapeutics L.P., Greenfield Ventures L.P,, Seven Seas Hill Corp., Ophir Green Corp., Purdue Pharma of Puerto Rico, Avrio Health L.P., Purdue Pharmaceutical Products L.P., Purdue Neuroscience Company, Nayatt Cove Lifescience Inc., Button Land 1.P., Rhodes Associates L.P., Paul Land Ine., Quidnick Land L.P., Rhodes Pharmaceuticals L.P., Rhodes Technologies, UDF LP, SVC Pharma LP, and SVC Pharma Inc. The Debtors’ corporate

crisis. See In re Purdue Pharma L.P., --- B.R. ----, 2021 WL 4240974, at *2 (Bankr. S.D.N.Y, Sept. 17, 2021). The case is particularly unique and complex in part because the Debtors’ assets “include enormous claims against their controlling shareholders, and in some instances directors and officers, who are members of the Sackler family.” Ud. at *3). L. Purdue Seeks Bankruptcy Relief in September 2019 Facing over 2,600 lawsuits related to its marketing of opioid medications, Purdue filed for bankruptcy relief on September 15, 2019. (See Bankruptcy Dckt., No. 1, No. 3787 at 28). Many of the lawsuits “sought to hold the Debtors and other parties jointly and severally liable for injuries related to opioid use” and “name certain of the Debtors’ officers, directors, and shareholders, including members of the Sackler Families, as defendants.” (Bankruptcy Dekt., No, 3787, at 28). Soon thereafter, the Bankruptcy Court enjoined the lawsuits against Purdue and hundreds of additional lawsuits against members of the Sackler family. See In re Purdue Pharma L.P., 2021 WL 4240974, at *30 n.5; Bankruptcy Dckt., No. 2983, at 171. This Court affirmed that preliminary injunction. Dunaway v. Purdue Pharma. L.P. Purdue Pharma, L.P.), 619 BR. 38 (S.D.N_Y. 2020). The Bankruptcy Court then set a July 30, 2020, deadline for everyone holding a pre-petition claim against Purdue to file proofs of claim against it. (Bankruptcy Dekt., No. 1221). Roughly 618,000 claimants did so. In re Purdue Pharma L.P., 2021 WL 4240974, at *1. These claimants include “the Federal Government, most of the States, thousands of political subdivisions, hundreds of Native American Tribes, more than 130,000 personal injury victims, and numerous hospitals, third party payors, ratepayers, public schools, and others.” (See Bankruptcy Dckt., No. 3787, at

headquarters is located at One Stamford Forum, 201 ‘Tresser Boulevard, Stamford, CT 06901. See In re Purdue Pharma L.P., No. 19-23649-RDD (hereinafter “Bankruptcy Dekt.”), Dkt, 3787, at FN 1.

28). 2. Parties Raise Objections to the Bankruptcy Plan’s Non-Debtor Releases On June 3, 2021, the Bankruptcy Court approved Purdue’s disclosure statement of its proposed plan. (See Bankruptcy Dckt., No. 2988). Section 10.7(b) of that proposed plan included releases of causes of action against all “Shareholder Released Parties” (the “Non-Debtor Releases”), which it defined to include the “Sackler Family Members”—which it in turn defined to include Raymond and Mortimer Sackler, any of their descendants, current and former spouses, and any of their estates, as well as six other categories of individuals and entities. (See Bankruptcy Dekt., No. 3726, at 34-36, 126-127). On July 19, 2021, the U.S. Trustee (who is not a claimant) objected to confirmation of the plan, arguing that the Non-Debtor Releases are unconstitutional, violate the Bankruptcy Code, and

are inconsistent with Second Circuit law. (See Bankruptcy Dekt., No, 3256). Certain others filed similar objections to the plan,? and the Department of Justice filed a statement regarding the Shareholder Releases. (See Bankruptcy Dckt., No. 3268). On September 1, 2021, the Bankruptcy Court rendered an oral ruling, stating it would confirm the proposed plan provided certain changes were made to it. (See Bankruptcy Dekt., No. 3731). Purdue filed the final version of its plan (the “Plan”) the next day. (Bankruptcy Dekt., No. Dkt. 3726). While narrowing certain language, the Plan still contained broad Non-Debtor Releases in Section 10.7(b), as well as broad definitions of “Releasing Parties,” and “Shareholder Released Parties” all of which remains the subject of significant objections by the U.S. Trustee and certain claimants (and which are now the subject of these appeals before this Court). (See Bankruptcy

3 The States of California, Connecticut, Delaware, Maryland, Oregon, Rhode Island, Washington, Vermont, and the District of Columbia, the City of Seattle, four Canadian municipalities, two Canadian First Nations and three pro se objectors. (Bankruptcy Dckt., No. 3787, at 28; see also No. 3594).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Nken v. Holder
556 U.S. 418 (Supreme Court, 2009)
Kelly v. Honeywell Int'l, Inc.
933 F.3d 173 (Second Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
In Re: Purdue Pharma L.P., Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-purdue-pharma-lp-nysd-2021.